-DARA BioSciences, Inc.}}/a}} (NASDAQ: DARA) now meets requirements to trade on the the Nasdaq exchange.
The Raleigh company said that the Nasdaq notified the drug firm on Tuesday that it had regained compliance with listing requirements. The company lost compliance when its stock price fell below $1, the minimum price the exchange requires for a stock listing. DARA was trading at $1.03 per share this morning.
DARA focuses on oncology and oncology supportive care products. Late last year, the company launched Soltamox, a liquid version of the breast cancer drug tamoxifen. The company plans a launch of Gelclair, a gel that coats the surface of the mouth covering lesions caused by radiotherapy or chemotherapy.
